Adjuvant and Neoadjuvant Therapy, Treatment for Advanced Disease, and Genetic Considerations for Adrenocortical Carcinoma: An Update from the SSO Endocrine and Head and Neck Disease Site Working Group

Paxton V. Dickson*, Lawrence Kim, Tina W.F. Yen, Anthony D Yang, Elizabeth G. Grubbs, Dhavel Patel, Carmen C. Solórzano

*Corresponding author for this work

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

This is the second of a two-part review on adrenocortical carcinoma (ACC) management. While margin-negative resection provides the only potential cure for ACC, recurrence rates remain high. Furthermore, many patients present with locally advanced, unresectable tumors and/or diffuse metastases. As a result, selecting patients for adjuvant therapy and understanding systemic therapy options for advanced ACC is important. Herein, we detail the current literature supporting the use of adjuvant mitotane therapy, consideration of adjuvant radiation therapy, and utility of cytotoxic chemotherapy in patients with advanced disease. Ongoing investigation into molecular targeted agents, immunotherapy, and inhibitors of steroidogenesis for the treatment of ACC are also highlighted. Lastly, the importance of genetic counseling in patients with ACC is addressed as up to 10% of patients will have an identifiable hereditary syndrome.

Original languageEnglish (US)
Pages (from-to)3453-3459
Number of pages7
JournalAnnals of surgical oncology
Volume25
Issue number12
DOIs
StatePublished - Nov 1 2018

Fingerprint

Adrenocortical Carcinoma
Inborn Genetic Diseases
Neoadjuvant Therapy
Neck
Head
Mitotane
Genetic Counseling
Therapeutics
Immunotherapy
Radiotherapy
Neoplasm Metastasis
Recurrence
Drug Therapy
Neoplasms

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

@article{a3c7a3a0cb2f404088539057116a681d,
title = "Adjuvant and Neoadjuvant Therapy, Treatment for Advanced Disease, and Genetic Considerations for Adrenocortical Carcinoma: An Update from the SSO Endocrine and Head and Neck Disease Site Working Group",
abstract = "This is the second of a two-part review on adrenocortical carcinoma (ACC) management. While margin-negative resection provides the only potential cure for ACC, recurrence rates remain high. Furthermore, many patients present with locally advanced, unresectable tumors and/or diffuse metastases. As a result, selecting patients for adjuvant therapy and understanding systemic therapy options for advanced ACC is important. Herein, we detail the current literature supporting the use of adjuvant mitotane therapy, consideration of adjuvant radiation therapy, and utility of cytotoxic chemotherapy in patients with advanced disease. Ongoing investigation into molecular targeted agents, immunotherapy, and inhibitors of steroidogenesis for the treatment of ACC are also highlighted. Lastly, the importance of genetic counseling in patients with ACC is addressed as up to 10{\%} of patients will have an identifiable hereditary syndrome.",
author = "Dickson, {Paxton V.} and Lawrence Kim and Yen, {Tina W.F.} and Yang, {Anthony D} and Grubbs, {Elizabeth G.} and Dhavel Patel and Sol{\'o}rzano, {Carmen C.}",
year = "2018",
month = "11",
day = "1",
doi = "10.1245/s10434-018-6750-9",
language = "English (US)",
volume = "25",
pages = "3453--3459",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "12",

}

Adjuvant and Neoadjuvant Therapy, Treatment for Advanced Disease, and Genetic Considerations for Adrenocortical Carcinoma : An Update from the SSO Endocrine and Head and Neck Disease Site Working Group. / Dickson, Paxton V.; Kim, Lawrence; Yen, Tina W.F.; Yang, Anthony D; Grubbs, Elizabeth G.; Patel, Dhavel; Solórzano, Carmen C.

In: Annals of surgical oncology, Vol. 25, No. 12, 01.11.2018, p. 3453-3459.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Adjuvant and Neoadjuvant Therapy, Treatment for Advanced Disease, and Genetic Considerations for Adrenocortical Carcinoma

T2 - An Update from the SSO Endocrine and Head and Neck Disease Site Working Group

AU - Dickson, Paxton V.

AU - Kim, Lawrence

AU - Yen, Tina W.F.

AU - Yang, Anthony D

AU - Grubbs, Elizabeth G.

AU - Patel, Dhavel

AU - Solórzano, Carmen C.

PY - 2018/11/1

Y1 - 2018/11/1

N2 - This is the second of a two-part review on adrenocortical carcinoma (ACC) management. While margin-negative resection provides the only potential cure for ACC, recurrence rates remain high. Furthermore, many patients present with locally advanced, unresectable tumors and/or diffuse metastases. As a result, selecting patients for adjuvant therapy and understanding systemic therapy options for advanced ACC is important. Herein, we detail the current literature supporting the use of adjuvant mitotane therapy, consideration of adjuvant radiation therapy, and utility of cytotoxic chemotherapy in patients with advanced disease. Ongoing investigation into molecular targeted agents, immunotherapy, and inhibitors of steroidogenesis for the treatment of ACC are also highlighted. Lastly, the importance of genetic counseling in patients with ACC is addressed as up to 10% of patients will have an identifiable hereditary syndrome.

AB - This is the second of a two-part review on adrenocortical carcinoma (ACC) management. While margin-negative resection provides the only potential cure for ACC, recurrence rates remain high. Furthermore, many patients present with locally advanced, unresectable tumors and/or diffuse metastases. As a result, selecting patients for adjuvant therapy and understanding systemic therapy options for advanced ACC is important. Herein, we detail the current literature supporting the use of adjuvant mitotane therapy, consideration of adjuvant radiation therapy, and utility of cytotoxic chemotherapy in patients with advanced disease. Ongoing investigation into molecular targeted agents, immunotherapy, and inhibitors of steroidogenesis for the treatment of ACC are also highlighted. Lastly, the importance of genetic counseling in patients with ACC is addressed as up to 10% of patients will have an identifiable hereditary syndrome.

UR - http://www.scopus.com/inward/record.url?scp=85053445529&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053445529&partnerID=8YFLogxK

U2 - 10.1245/s10434-018-6750-9

DO - 10.1245/s10434-018-6750-9

M3 - Article

C2 - 30218246

AN - SCOPUS:85053445529

VL - 25

SP - 3453

EP - 3459

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 12

ER -